Circulating tumor DNA (ctDNA) provides a potential non-invasive biomarker for cancer diagnosis and prognosis, but whether it could reflect tumor heterogeneity and monitor therapeutic responses in hepatocellular carcinoma (HCC) is unclear. Focusing on 574 cancer genes known to harbor actionable mutations, we identified the mutation repertoire of HCC tissues, and monitored the corresponding ctDNA features in blood samples to evaluate its clinical significance. Analysis of 3 HCC patients' mutation profiles revealed that ctDNA could overcome tumor heterogeneity and provide information of tumor burden and prognosis. Further analysis was conducted on the 4th HCC case with multiple lesion samples and sequential plasma samples. We identified 160 subclonal SNVs in tumor tissues as well as matched peritumor tissues with PBMC as control. 96.9% of this patient's tissue mutations could be also detected in plasma samples. These subclonal SNVs were grouped into 9 clusters according to their trends of cellular prevalence shift in tumor tissues. Two clusters constituted of tumor stem somatic mutations showed circulating levels relating with cancer progression. Analysis of tumor somatic mutations revealed that circulating level of such tumor stem somatic mutations could reflect tumor burden and even predict prognosis earlier than traditional strategies. Furthermore, HCK (p.V174M), identified as a recurrent/metastatic related mutation site, could promote migration and invasion of HCC cells. Taken together, study of mutation profiles in biopsy and plasma samples in HCC patients showed that ctDNA could overcome tumor heterogeneity and real-time track the therapeutic responses in the longitudinal monitoring.
of methods for diagnosing and monitoring HCC burden include imaging techniques [ultrasound imaging (US), computed tomography (CT) imaging, magnetic resonance imaging (MRI)] and alpha-fetoprotein (AFP) test. However, these methods failed to provide accurate evaluation of prognosis.
Circulating tumor DNA (ctDNA), carrying tumor special genomic alterations, has been widely investigated as a diagnostic/prognostic biomarker in various cancers. 7 It can comprehensively reflect tumor genomic features, including both genetic and epigenetic variants originating from different tumor lesions, and thus serves as a potential non-invasive surrogate for tumor tissue biopsies, especially when tumor biopsy specimens are difficult to obtain. 8, 9 Therefore, it is expected to be an effective tool to overcome tumor heterogeneity and track tumor burden during the treatment-driven clonal evolution. 10 Several studies have focused on revealing the association between ctDNA features and HCC progression by elaborate analysis of different ctDNA characteristics including concentration, methylation, microsatellite alteration, point mutation, chromosomal rearrangement and viral DNA integration, with all these characteristics in ctDNA show similar patterns when compared with primary tumor tissues. 11 However, these findings fail to provide a confident way for real-time monitoring therapeutic responses since they were limited to only study several specific genes and thus lack the power to overcome tumor heterogeneity. As tumor burden and progression are accompanied with generation and accumulation of somatic mutations, the mutation spectrum in ctDNA should be of great importance for providing information of tumor burden and metastasis status. 12, 13 However, whether profiling of tumor mutations in ctDNA could reflect tumor burden during HCC progression still need further investigation. Here we present extensive analysis of mutation profiles from 4 HCC patients to investigate the dynamics of cancer driven genomic mutations in serial plasma samples for evaluating ctDNA's clinical value.
Material and Methods

Sample collection and DNA extraction
The samples were collected from 4 patients who received treatment in Mengchao Hepatobiliary Hospital of Fujian Medical University. For 3 of these patients (defined as Patient 1, 2 and 3), primary tumor tissues, portal vein tumor thrombus, matched peritumor tissues, and corresponding plasma samples from pre-surgery, post-surgery and follow-up were collected. For the other patient (defined as Patient 4), primary HCC tissue and matched peritumor tissue from the first surgery, and other 4 recurrent/metastatic tumor tissues from the second surgery were collected; meanwhile, the corresponding plasma samples from different time points were also collected. All tumor tissues from hepatectomy were trimmed by an experienced pathologist to remove as much normal liver tissues as possible; the final obtained tumor tissues should have at least 80% HCC cells confirmed by H&E staining. Afterwards, the specimen was dissected into approximately 0.5 3 0.5 3 0.5 cm 3 blocks, and then freezed into liquid nitrogen before DNA extraction. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples collected before hepatectomy, using Ficoll-Paque PLUS kit (GE Healthcare) according to the manufacturer's instructions. Total genomic DNA from primary tumor tissues, peritumor tissues, recurrent/metastatic tumor tissues and PBMCs were extracted using QIAamp DNA mini Kit (Qiagen) according to manufacturer's instructions. For cell-free DNA extraction, the peripheral blood was collected into EDTA tubes and subjected to centrifugation at 820 g for 10 min within one hour of sampling to minimize the DNA degradation and leukocyte lysis; afterward, the isolated plasma was transferred into sterilized tubes and centrifuged at 16,000 g for 10 min, and the final obtained supernatant was stored at 2808C before extraction; the circulating DNA was extracted from 4 mL of plasma samples using QIAamp Circulating Nucleic Acid kit (Qiagen) according to the manufacturer's instructions. All human sample collection procedures and the usage of human samples were approved by the Institution Review Board of Mengchao Hepatobiliary Hospital of Fujian Medical University. The written consents were received from the participated patients in this study.
Target sequencing
DNA from tissue samples collected from 3 patients (Patient 1, 2 and 3), and plasma samples as well as PBMCs collected from all patients were subjected to DNA library preparation following manufacturer's instructions, and the targeted enrichment was performed using the Agilent SureSelect customized platform, which captures 2.5 Mb of known coding DNA sequences (CDS) from 574 known cancer-associated What's new? Hepatocellular carcinoma (HCC) is a heterogenous disease, with significant variability in morphology, molecular alterations, and progression. Accurately evaluating the prognosis of this complicated disease is challenging but could potentially overcome through the use of circulating tumor DNA (ctDNA), according to the present study. Analysis of mutation profiles in HCC patients showed that more than 98% of subclonal mutations are captured in ctDNA. The majority of changes in circulating levels of subclonal mutations were correlated to tumor burden. By providing real-time information on tumor lesions, the screening of somatic ctDNA alterations could facilitate tumor burden tracking and enable earlier prognostic determination.
genes. Then, the obtained libraries were used for targeted sequencing on an Illumina HiSeq 4000 sequencer at Beijing Novogene Bioinformatics Technology Co., Ltd. (Beijing, China).
Whole exome sequencing
DNA from tissue samples collected from the Patient 4 were subjected to DNA library preparation following the manufacturer's instructions, and the targeted enrichment of whole exomes was performed through using Agilent SureSelect Human All Exon V6. Then, the final obtained libraries were used for whole exome sequencing on an Illumina HiSeq 2000 sequencer at Beijing Novogene Bioinformatics Technology Co., Ltd. (Beijing, China).
Sequencing data analysis and mutation calling
Mapping paired-end alignment of sequencing reads to the hg19 genome was performed using Burrows-Wheeler Aligner (version 0.7.8) for both whole exome-sequencing data and target sequencing data. Picard was used to mark duplicates of PCR product. Pileup files were generated using samtools 1.0.
Tumor subclonal mutations were detected using Bioconductor package deepSNV version 1.18.1.
14 Using a betabinomial model and a likelihood ratio test, the deepSNV algorithm can discriminate sequencing errors and subclonal SNVs. This algorithm was applied on both whole exomesequencing data and target sequencing data. All detecting parameters were set to default according to deepSNV documentation, with minimum coverage 3 for tissue samples and 3 for plasma samples. The detection regions were based on the genomic position of 574 significantly cancerrelated genes' exons (Supporting Information Table S1 ). A SNV is identified if its adjusted p values 0.05, which was calculated by Benjamini & Hochberg (BH) adjustment method for multiple testing corrections. All identified mutations were further annotated with wANNOVAR for both genes and functions. 15 Somatic mutations were further filtered under following criteria: (1) no mutant reads of the allele were observed in control samples; (2) minimal of 3 mutant reads were observed in at least one tissue sample.
Clonal population structure analysis using PyClone Clonal population was investigated using PyClone, 16 a clustering method which groups mutations into putative clonal clusters to estimate the cellular prevalence based on allelic imbalances caused by copy-number variants and normal-cell contamination. PyClone needs two kinds of information to infer the clonal population structure of each sample, including copy number and depth of coverage for each mutation under analysis.
Copy number information for location of each analyzed mutation was obtained using Bioconductor package CopyWriteR, which calculate copy number according to off-target reads information of targeted sequencing data files. The package outputs segmented logarithmic depth of coverage ratios (logR). A threshold of 0.25 was used to determine copy number variation, which means segments with logR below 20.25 would be assigned a copy number of 1 and segments with logR above 0.25 would get a copy number of 3. Hg19 was used as reference genome with a bin size of 50k. For each analyzed sample, CopyWriteR was applied with PBMCs as control in copy number prediction. If CopyWriteR algorithm was unable to provide copy number information at a given mutation location, nearest valid copy number will be used instead.
Depth of coverage information was obtained using bam2R function from Bioconductor package deepSNV. This algorithm was applied to each sequencing data with a quality threshold of 10 to determine if the reads should be recorded. Copy number and depth of coverage information obtained above was then inputted into PyClone to infer the clonal population structure of each sample. All parameters were set as default value and the algorithm was run using binomial model with the "total_copy_number" option.
Construction of cell lines overexpressing wild type and mutated HCK
To study functions of HCK mutant (p.V174M) in HCC cells, the cDNAs of wild type HCK gene (NCBI protein id: NP_001165600.1) and HCK mutant (p.V174M) were cloned into plasmid vector (pCDH-CMV-MCS-EF1-copGFP), and the empty vector was taken as negative control (termed as Mock). Afterwards, SMMC7721 cells were transfected with corresponding plasmids using the Lipofectamine 3000 according to the manufacturer's protocol. The cells were then harvested after 48 hr of transfection and further used for in vitro analysis.
Cell migration and invasion assay
The migration assays were carried out using Transwell units (No. PIEP12R48; Millipore, Billerica, MA) and the invasion ability was assessed using the Transwell units coated with Matrigel (No. 356234; BD Biosciences, New York, NY) according to the manufacturer's instructions. Briefly, the cells (3 3 10 5 cells/mL, 100 lL) were cultured at the upper compartment of the chamber in serum-free DMEM supplemented with 0.5% BSA for 48 hrs, and the lower compartment of the chamber was filled with DMEM supplemented with 10% FBS. After 48 hrs of incubation, the filters were harvested, fixed with paraformaldehyde, and stained with crystal violet. Tumor cells on the upper surface of the filters were removed by wiping with cotton swabs. Cells that had passed through the filter to the lower surface were counted under a microscope in five different fields at 203 magnification.
Result
Mutation profiles of 3 HCC patients
To investigate tumor heterogeneity and the potential of ctDNA as a biomarker in HCC, we used a custom gene panel containing 574 cancer associated genes known to harbor actionable mutations to capture mutations associated with tumor development (Supporting Information Table S1 ). Target sequencing was performed on 9 tissue samples and 8 plasma samples from 3 patients with mean coverage of 1607 3 and 9663, respectively.
Bioconductor Package deepSNV was used to identify subclonal mutations in each of the tumor samples with adjacent normal tissue as control. In total, 204-253 subclonal mutations were identified in the 3 patients, suggesting that these mutations may take part in tumor development. Detailed information of identified subclonal mutations was available in Supporting Information Table S2 . Only 47.4 to 79.4% of subclonal mutations were shared between primary tumor and PVTT in each of the patients, indicating high tumor heterogeneity (Fig. 1a) . Analysis of mutation frequency in corresponding plasma samples showed that 98.02 to 99.01% of identified subclonal mutations were well captured in ctDNA, indicating that ctDNA could serve as a potential tool for overcoming tumor heterogeneity.
According to patients' clinical course, 61.64% to 94.12% of all subclonal mutations showed circulating level changes correlated to patients' tumor burden, with lower fraction of mutated allele in plasma samples collected after hepatectomy and higher mutation frequency during recurrence (Fig. 1b) . These mutations have different ability to reflect clinical dynamics due to their distinct variation patterns among serial of plasma samples. Mutations with drastic changes between pre-and post-surgery may provide better way to monitor patients' prognosis, consistent with image findings (Supporting Information Fig. S1 ).
These results suggested that ctDNA could overcome tumor heterogeneity and provide potential tool for monitoring clinical response. However, it's still more valuable to filter out tumor specific mutations for better clinical utilization.
CtDNA capturing tumor heterogeneity in a patient with multiple tumor lesions
To better identify mutations reflecting patient's tumor burden and prognosis, a clinical case of 58 years old patient was chosen for further analysis. This patient (Patient 4) was diagnosed with HCC combining with decompensate hepatitis-Brelated cirrhosis, and sequentially received surgery, TACE (Transhepatic Arterial Chem Otherapy And Embolization), the second surgery, radiotherapies, targeted drug therapy (Sorafenib) and finally TACE over one 1-year clinical course. Primary HCC sample (T1) and matched peritumor sample (N1) were obtained at the first partial hepatectomy; other tumor samples were collected 5 months later at the second surgical resection (samples from recurrent sites in segment VII and V of liver were labeled R1 and R2, respectively, and samples from metastatic deposits in PVTT and extrahepatic lymph nodes were labeled M1 and M2, respectively). Detailed One hundred and sixty subclonal SNVs were identified by deepSNV algorithm in tumor tissues and matched peritumor tissues with PBMCs as control (Fig. 2c and Supporting Information Table S3 ). Among these mutations, 11 stem mutations were common among all tissue samples, 45 of them were shared in all cancer tissues, 14 were specifically related with recurrences/metastases and others were unclassified since they did not follow any clear distribution pattern (Fig.  2c) . Consistent with previous results, heterogeneity was shown across all tissue samples, as 65% of these mutations were not shared among tumor samples, which suggests cancer evolution during tumorigenesis and metastasis. This high heterogeneity could be a great obstacle for obtaining complete genetic information of tumor. Surprisingly, sequencing analysis of circulating DNA showed that 96.8% of these mutations were well captured in plasma samples, indicating a potential tool for overcoming tumor heterogeneity. Furthermore, the Bayesian clustering algorithm PyClone was applied to characterize these subclonal mutations, and 9 mutation clusters were clearly identified (Fig. 2d) . Significantly, 5 of these 9 subclonal mutation clusters showed higher cellular frequency and allele fraction in all tumor samples, which indicates these subclonal mutations may participate in cancer tumorigenesis. Meanwhile, circulating allele frequency in plasma of these identified mutation clusters during the course of comprehensive therapy was shown in Figure 2e . Among all subclonal mutation clusters, only circulating allele fraction of mutation cluster 8 and 9 showed dynamic change corresponding to tumor burden. In consistent with imaging findings, these 2 mutation clusters showed higher circulating mutant fraction correlating to increase of tumor burden during different stages of recurrences/metastases, and lower circulating mutant fraction corresponding to decreasing mass of tumor tissue resulted from surgical excision. Further annotation of these mutations showed that nearly all of them were somatic mutations, since no mutant reads could be detected in PBMCs.
Somatic mutation frequency of ctDNA reflecting clinical dynamics corresponding to sequential therapy
To investigate whether somatic mutations play crucial roles in cancer progression and metastasis, 37 somatic mutations were extracted from 160 subclonal mutations identified by deepSNV (Supporting Information Table S4 ), 4 of these somatic mutations were commonly shared in all tissue samples including peritumor tissues, 13 commonly shared in all tumor tissues, whereas only 1 mutation (termed as HCK p.V174M) was specifically occurred in all recurrent/metastatic tumor tissues (Fig. 3a) . Furthermore, 68-89% of primary somatic mutations also could be detected in the recurrent/ metastatic tumors (Supporting Information Table S4 ), suggesting the mutation spectrum could be utilized to track the possible origin of these recurrences/metastases. Branched evolution of tumor can be visualized from the phylogenetic trees constructed based on somatic mutation distributions (Fig.  3b) . Further analysis identified 6 mutation clusters according to their allele frequency in tissue samples using PyClone (Fig.  3c) , and 3 mutation clusters (cluster 4, 5, 6) showed increasing cellular frequency in tumor tissues compared with peritumor tissues while other clusters showed similar cellular frequency across all tissue samples including peritumor, suggesting that these 3 mutation clusters may be related to tumorigenesis.
Applying Bayesian clustering algorithm based on plasma distributions classified these somatic mutations into 3 mutation clusters (Fig. 3d) . Among these identified mutation clusters, cluster 1 (including 19 somatic mutations) had similar cellular frequency in all plasma samples, while the other 2 mutation clusters (including 18 somatic mutations in total) showed dynamic cellular frequency change in plasma samples corresponding to tumor burden and cancer progression status. Surprisingly, the majority of these mutations (14/18) were belonged to tumor stem mutations or metastatic stem mutations. Meanwhile, these 14 tumor mutations could be identified as so called "real" somatic mutations since no such mutant allele reads were observed in peritumor tissues. It is reasonable that circulating level of these mutations could dynamically reflect cancer progression because they originated during the transformation of tumor cells and thus can represent the majority of tumor lesions. This also makes them better candidates for monitoring tumor burden. All results further demonstrated that more significant tumorrelated mutations could be screened using peritumor as control compared with PBMCs. Taken together, these results suggest that tracking tumor stem somatic mutation frequency in patients' plasma samples may provide potential valuable strategy for real-time monitoring tumor burden and evaluating prognosis outcomes.
HCC-derived ctDNA for tumor burden monitoring
In the longitudinal monitoring of Patient 4 during the course of comprehensive therapy, 8 somatic nonsynonymous mutations were extracted from the 14 mutations with cellular frequency dynamically corresponding to tumor burden, including 5 non-synonymous, 2 frameshift deletion, and 1 stop-gain (Fig. 3e and Supporting Information Table S5 ). Furthermore, after the first TACE treatment, the increasing circulating level of above extracted 8 somatic mutations were observed even before imaging diagnosis and the increase of AFP levels, suggesting that ctDNA could serve as a better tool for early diagnosis and prognosis of HCC.
Interestingly, 1 non-synonymous somatic mutation (HCK p.V174M) among these 14 mutations was only detected specifically in recurrent/metastatic tumor while remain undetectable in primary HCC. This mutation was previously identified as COSM1743471, which was reported to be associated with intrahepatic cholangiocarcinoma and pancreatic cancer according to cancer mutation database COSMIC. 17 In our study, it was first identified in plasma P3 with allele frequency equal to 0.9% after the first TACE treatment, and became undetectable after second surgery, while sharply increased during the second recurrence (Fig. 3f) . Its exclusive detection in the recurrent/metastatic tumors suggests it might be a key determinant mutation site of HCC recurrence/ metastasis.
Taken together, our results suggested that circulating level of those "real" somatic mutations could provide a possible solution for monitoring tumor burden and dynamically reflect prognosis. This conclusion also could be validated in the other 3 patients who we previously sequenced (Supporting Information Table S6 and Supporting Information Fig.  S4 ), with such "real" somatic mutations showing high correlation with clinical dynamics, which could be utilized as novel HCC biomarkers.
Overexpression of HCK mutant enhancing migration and invasion of HCC cells
To further investigate the biological functions of HCK mutation (p.V174M), SMMC7721 cells were used for overexpression the wild type HCK or mutated HCK. As shown in Figure 3g , overexpression of wild type or mutated HCK was successfully conducted in SMMC7721 cells. Afterwards, migration and invasion assays were further evaluated in the Transwell system. The results showed that both of the wild type and mutated HCK overexpressed SMMC7721 cells have stronger migration and invasion abilities than the negative control cells (Mock), as shown in Figures 3h and 3i , which is consistent with previous reports regarding the HCK functions in other cancers. 18, 19 Noteworthily, the expression of HCK mutant (p.V174M) further significantly enhanced the invasion ability of cancer cells comparing with the HCK wild type overexpressed cells (Figs. 3h and 3i) ; meanwhile, we also could observe the tendency of enhancing migration ability by HCK mutation although the difference did not achieve statistical significance (p 5 0.102). HCK, a Src family tyrosine kinase and a direct target of ibrutinib, could enhance tumorassociated macrophage migration and matrix remodeling to promote invasive capacity of tumor cells in a MMPdispensable manner. 18, 19 Although there is no related studies regarding the biological functions of HCK in HCC, it has been reported that HCK activation played important roles in podosome formation which contributed to cancer cell dissociation from the primary tumor and seeding into distal organs. 20 The mutation of p.V174M in HCK takes place in the SH2 domain, which conformation is crucial for the HCK protein activation; therefore, this mutation may lead to abnormal activation of HCK, which could promote tumor cell invasion. However, the detailed mechanism still needs further investigation.
Discussion
Circulating tumor DNA has several features such as genetic and epigenetic alterations, all of which have shown significant correlation with tumor progression, and thus could be utilized for novel biomarker development. Among these features, mutation spectrum covering multiple mutation sites could provide comprehensive information regarding tumor progression, actionable genomic alterations and therapeutic resistance mechanisms, and therefore could be an ideal tool for diagnosis and prognosis of HCC. Tumor heterogeneity is an intrinsic feature of HCC, which would be a major obstacle for optimizing effective anticancer treatments. While this problem could be partially settled by multisampling biopsy, this strategy would bring numerous side effects including risk of infection and bleeding. In contrast, ctDNA as a novel non-invasive biomarker could significantly overcome intra-heterogeneity due to its origination from multiple tumor lesions without above limitation.
Carcinogenesis of HCC is accompanied by accumulation of genetic alterations during the process of long-term chronic hepatitis, most of which were induced by HBV or HCV infections. 21 Although peritumor is defined as cytological normal-appearing cells from which tumor may arise, 22, 23 it already contains multiple genetic changes during early tumorigenesis comparing with PBMCs, while still lacks of mutations crucial for malignant transformation. At present, a number of researchers used PBMCs as control for tumor somatic mutation screening in HCC because of its germline character. 12, 13 However, our results suggest screening of somatic ctDNA alteration based on peritumor tissue rather than PBMCs would provide information of "real" somatic mutations to reflect majority of tumor lesions because of their origination during malignant transformation. These mutations are related to tumor development in HCC and thus have higher clinical potential for monitoring tumor burden. Future study should consider the genetic background provided by peritumor for acquisition of accurate clinical information, although sometimes tissue samples could be difficult to obtain.
Optimization of the drug treatment strategy according to its therapeutic response is crucial for improving clinical outcome of cancer treatment. Our research showed that genomic alterations related to drug targets could be detected in ctDNA, which suggest that analysis of circulating mutation spectrum may provide detailed information for guiding drug treatment, along with monitoring of gained mutations related to drug resistance. In summary, the circulating level of tumor somatic mutations can be employed to reflect tumor burden in real time and overcome intra-tumor genetic heterogeneity presented in advanced HCC patients during the comprehensive treatment and follow-up. Furthermore, monitoring ctDNA could track HCC burden earlier than traditional strategies including imaging findings and measurement of AFP levels. However, since those analyses were carried out mainly on a single HCC patient with multiple tumor lesions and serial plasma samples and validated in a small set of patients, the results still need to be further confirmed in large cohort. Despite the clinical significance of ctDNA, further studies dedicating to its clinical translation still need to overcome following challenges: (1) extra read depth is still required by sequencing of ctDNA due to its low DNA concentrations, (2) more reliable methods for mutation site filtering, (3) novel algorithm for characterization of mutation with extreme low frequency.
